Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 10/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 9/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.58 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28135987 | 0.98 | CYP11B1 (0.97) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| Iodide SCHEMBL28192688 | 0.98 | CYP11B1 (0.97) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL30523909 | 0.87 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL15179016 | 0.87 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL30523908 | 0.87 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL2776942 | 0.86 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL6992090 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP19A1TBXAS1MEN1 | |
| SCHEMBL17450431 | 0.82 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL11620329 | 0.82 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL15373316 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114072444-B | Curable composition, cured product, overcoat film, flexible wiring board, and method for producing same | 日保丽公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| CN-107873015-B | Crystal germanosilicate material with novel CIT-13 topological structure and preparation method thereof | 加州理工学院 | 2021-12-24 | — | — | CN | disclosed |
| US-10828625-B2 | Crystalline germanosilicate materials of new CIT-13 topology and methods of preparing the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-10 | — | — | US | disclosed |
| US-10717071-B2 | Crystalline germanosilicate materials of new CIT-13 topology and methods of preparing the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190247835-A1 | Crystalline Germanosilicate Materials Of New CIT-13 Topology And Methods Of Preparing The Same | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-08-15 | — | — | US | disclosed |
| US-10293330-B2 | Crystalline germanosilicate materials of new CIT-13 topology and methods of preparing the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190083962-A1 | Crystalline Germanosilicate Materials Of New CIT-13 Topology And Methods Of Preparing The Same | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-03-21 | — | — | US | disclosed |
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-3303221-A1 | CRYSTALLINE GERMANOSILICATE MATERIALS OF NEW CIT-13 TOPOLOGY AND METHODS OF PREPARING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1675578-A2 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| EP-1620082-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005039548-A2 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | PROBIODRUG AG (DE) | 2005-03-17 | — | — | US | disclosed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098625-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717071-B2 | Crystalline germanosilicate materials of new CIT-13 topology and methods of preparing the same | ATG13, CIT, MICOS13 | CYP11B1 3779/4885CYP11B2 4147/4885CYP19A1 4036/4885 |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | GLS, GLUL, GLS2 | CYP11B1 2572/4885CYP11B2 2600/4885CYP19A1 3760/4885 |
| US-10293330-B2 | Crystalline germanosilicate materials of new CIT-13 topology and methods of preparing the same | ATG13, SLC13A3, MICOS13 | CYP11B1 3672/4885CYP11B2 4169/4885CYP19A1 4348/4885 |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | GLS, QPCT, GLS2 | CYP11B1 2857/4885CYP11B2 2960/4885CYP19A1 827/4885 |
| US-20190083962-A1 | Crystalline Germanosilicate Materials Of New CIT-13 Topology And Methods Of Preparing The Same | ATG13, CIT, MICOS13 | CYP11B1 3779/4885CYP11B2 4147/4885CYP19A1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.